Israeli privately-held tech companies raised $12.2 billion in 2024, up 31% from 2023, Start-Up Nation Central (SNC) reported today. Of this figure, $10.6 billion was officially reported by the ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Teva Pharmaceutical ( NYSE: TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...